Nanobiotix S.A. (NBTX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Nanobiotix platform improves cancer drug delivery and bioavailability in mouse models
# 📝 What This Document Is 📰 This document is a Form 6-K press release (Exhibit 99.1) announcing that Nanobiotix presented new, highly technical preclinical data at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). Essentially, the company is providing an early look at
Nanobiotix S.A. — 6-K Filing
# 🧾 What This Document Is This is a standard regulatory filing from **Nanobiotix (NBTX)**. It’s not an earnings report or a press release about a big discovery—it’s a required, routine update to inform the market about the company's **share structure and voting power** as of March 31, 2026. 👉 **
March 2026
Nanobiotix S.A. — 6-K Filing
# 🧾 What This Document Is This is a **6-K filing** from Nanobiotix, which is a current report foreign companies file with the SEC to share major news. It contains a press release that serves as a comprehensive business update and a report of their full financial results for 2025. Think of it as the
Nanobiotix S.A. — 6-K Filing
# 🧾 What This Document Is This is a **6-K report**, which is a form foreign companies like Nanobiotix (based in France) use to tell the U.S. market about important events. This one is essentially a press release sharing the first clinical trial results for one of their key drugs, presented at a ma
SEC filings
All filings →Insider trades
All insider trades →Nanobiotix S.A. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Nanobiotix S.A.
All people →No officers or directors have been indexed for Nanobiotix S.A..